Stock NILE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Nile Therapeutics, Inc. Other OTC

Equities

US6541451018

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for Nile Therapeutics, Inc.
05-13 Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024
05-13 Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024
Capricor: Q1 Earnings Snapshot
AQ
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M
MT
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Capricor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
AQ
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting
CI
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
AQ
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
AQ
Transcript : Capricor Therapeutics, Inc. - Special Call
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
AQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
CI
Capricor Therapeutics to Present at Upcoming Investor Conferences
AQ
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
AQ
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference
CI
Capricor: Q4 Earnings Snapshot
AQ
Transcript : Capricor Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M
MT
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CAPR Stock
  4. Stock
  5. News Nile Therapeutics, Inc.